- Global Pharma News & Resources

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

SCYNEXIS, Inc. to Present at Upcoming Investor Conferences

PR Newswire

JERSEY CITY, N.J., Sept. 25, 2018

JERSEY CITY, N.J., Sept. 25, 2018 /PRNewswire/ -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company delivering innovative therapies for difficult-to-treat and often life-threatening infections, today announced that the Company will present at the following upcoming investor conferences:

  • The Ladenburg Thalmann 2018 Healthcare Conference at the Sofitel New York on Tuesday, October 2, 2018 at 10:30 a.m. ET.
  • Cantor Fitzgerald's Global Healthcare Conference at InterContinental New York Barclay on Wednesday, October 3, 2018 at 2:15 p.m. ET.

Live webcasts of the presentations will be available on the Investors section of the Company's website: A replay of each presentation will be available approximately two hours after the event and will be available for two weeks following each presentation.

SCYNEXIS, Inc. (NASDAQ:SCYX) is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by developing innovative therapies. The SCYNEXIS team has extensive experience in the life sciences industry, discovering and developing more than 30 innovative medicines over a broad range of therapeutic areas. SCYNEXIS's lead product candidate, ibrexafungerp (formerly SCY-078), is a novel oral/IV antifungal agent in Phase 2 clinical and pre-clinical development for the treatment of multiple serious and life-threatening invasive fungal infections caused by Candida and Aspergillus species. For more information, visit


Investor Relations
Natalie Wildenradt
Argot Partners
Tel: 212-600-1902

Media Relations
George E. MacDougall
MacDougall Biomedical Communications
Tel: 781-235-3093

View original content:


Editor Details

Last Updated: 25-Sep-2018